Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clinic experience

Leuk Lymphoma. 2024 Mar;65(3):389-393. doi: 10.1080/10428194.2023.2285236. Epub 2023 Nov 30.

Authors

Affiliations

¹ Department of Medicine, Mayo Clinic, Rochester, MN, USA.
² Division of Hematology, Mayo Clinic, Rochester, MN, USA.
³ Division of Neurology, Mayo Clinic, Rochester, MN, USA.
⁴ Department of Immunology, Mayo Clinic, Rochester, MN, USA.
⁵ Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.

PMID: 38031734
DOI: 10.1080/10428194.2023.2285236

No abstract available

MeSH terms

Antigens, CD19
Cell- and Tissue-Based Therapy
Cytokine Release Syndrome / etiology
Humans
Immunotherapy, Adoptive / adverse effects
Lymphoma, Large B-Cell, Diffuse* / therapy
Neurotoxicity Syndromes* / diagnosis
Neurotoxicity Syndromes* / etiology
Neurotoxicity Syndromes* / therapy
Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen* / genetics

Substances

Receptors, Chimeric Antigen
Antigens, CD19
Receptors, Antigen, T-Cell